Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI (TM) algorithm for cardiac amyloidosis (CA) -- the first and only cleared ...
Anumana’s innovative AI algorithms recognized for their transformative potential in cardiology - the first of which is now commercially available “At Anumana, we are committed to developing ...
Clinicians rely daily on electrocardiograms (ECG) to detect common cardiovascular conditions, but accurate diagnoses require high levels of expertise. In a new study that reviewed nearly 1 million ...
Artificial intelligence (AI)-based algorithms that use electrocardiogram (ECG) data have high accuracy in predicting ...
An artificial intelligence (AI) algorithm paired with the single-lead electrocardiogram (ECG) sensors on a smartwatch accurately diagnosed structural heart diseases, such as weakened pumping ability, ...
Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden death in adolescents and initial detection is often difficult. A new UC San Francisco study finds that Artificial Intelligence-enhanced ...
Southlake, TX, June 04, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (HSCS) (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial ...
The wearable ECG monitors market is witnessing significant growth, poised to expand from $4.78 billion in 2025 to $5.9 billion in 2026, at a compound annu ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, Inc., a leading AI-driven health technology company and portfolio company of nference, announced today it has received the 2024 MedTech Breakthrough Award ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results